Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy

被引：126

作者：

Desar, I. M. E. ^{[1
]}

van Herpen, C. M. L. ^{[1
]}

van Laarhoven, H. W. M. ^{[1
]}

Barentsz, J. O. ^{[2
]}

Oyen, W. J. G. ^{[3
]}

van der Graaf, W. T. A. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands

[2] Radboud Univ Nijmegen, Med Ctr, Dept Radiol, NL-6500 HB Nijmegen, Netherlands

[3] Radboud Univ Nijmegen, Med Ctr, Dept Nucl Med, NL-6500 HB Nijmegen, Netherlands

来源：

CANCER TREATMENT REVIEWS | 2009年 / 35卷 / 04期

关键词：

Cancer; Targeted therapy; Molecular imaging; Functional imaging; ENDOTHELIAL GROWTH-FACTOR; POSITRON-EMISSION-TOMOGRAPHY; RECOMBINANT HUMAN ENDOSTATIN; ADVANCED COLORECTAL-CANCER; TYROSINE KINASE INHIBITOR; ASSESSING TUMOR RESPONSE; VEGF RECEPTOR INHIBITOR; RENAL-CELL CARCINOMA; PHASE-I TRIAL; LIVER METASTASES;

D O I：

10.1016/j.ctrv.2008.12.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The development of targeted therapies is a major breakthrough in the treatment of cancer. By evoking necrosis and cavitation, evaluation based on tumour size alone, as is done in the RECIST criteria, is no longer an adequate method. New molecular and functional imaging techniques are developed. This review focuses on the use of new imaging modalities for the evaluation of treatment response of pathway based targeted therapies. First, the basic principles of functional and molecular imaging modalities are briefly discussed. Thereafter, their clinical application in targeted therapies is correlated to the underlying biological mechanism. in this way, the best method for response evaluation for a new agent can be identified. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：309 / 321

页数：13

共 132 条

[51]

Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab [J].

Hsiang, David J. ;

Yatnamoto, Maki ;

Mchta, Rita S. ;

Su, Min-Ying ;

Baick, Choong H. ;

Lane, Karen T. ;

Butler, John A. .

ARCHIVES OF SURGERY, 2007, 142 (09) :855-860

[52]

JAC J, 2008, J CLIN ONCOL

[53]

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume [J].

Jayson, GC ;

Parker, GJM ;

Mullamitha, S ;

Valle, JW ;

Saunders, M ;

Broughton, L ;

Lawrance, J ;

Carrington, B ;

Roberts, C ;

Issa, B ;

Buckley, DL ;

Cheung, S ;

Davies, K ;

Watson, Y ;

Zinkewich-Péotti, K ;

Rolfe, L ;

Jackson, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) :973-981

[54]

Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies [J].

Jayson, GC ;

Zweit, J ;

Jackson, A ;

Mulatero, C ;

Julyan, P ;

Ranson, M ;

Broughton, L ;

Wagstaff, J ;

Hakannson, L ;

Groenewegen, G ;

Bailey, J ;

Smith, N ;

Hastings, D ;

Lawrance, J ;

Haroon, H ;

Ward, T ;

McGown, AT ;

Tang, M ;

Levitt, D ;

Marreaud, S ;

Lehmann, FF ;

Herold, M ;

Zwierzina, H .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (19) :1484-1493

[55]

Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma [J].

Juweid, Malik E. ;

Stroobants, Sigrid ;

Hoekstra, Otto S. ;

Mottaghy, Felix M. ;

Dietlein, Markus ;

Guermazi, Ali ;

Wiseman, Gregory A. ;

Kostakoglu, Lale ;

Scheidhauer, Klemens ;

Buck, Andreas ;

Naumann, Ralph ;

Spaepen, Karoline ;

Hicks, Rodney J. ;

Weber, Wolfgang A. ;

Reske, Sven N. ;

Schwaiger, Markus ;

Schwartz, Lawrence H. ;

Zijlstra, Josee M. ;

Siegel, Barry A. ;

Cheson, Bruce D. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :571-578

[56]

Current concepts - Positron-emission tomography and assessment of cancer therapy [J].

Juweid, ME ;

Cheson, BD .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (05) :496-507

[57]

Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC) [J].

Karakunnel, J. J. ;

Gulley, J. L. ;

Arlen, P. M. ;

Mulquin, M. ;

Wright, J. J. ;

Turkbey, I. B. ;

Choyke, P. ;

Ahlers, C. M. ;

Figg, W. D. ;

Dahut, W. L. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[58]

Kauczor Hans-Ulrich, 2006, Cancer Imaging, V6, P51, DOI 10.1102/1470-7330.2006.0010

[59]

Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors [J].

Kawada, Kenji ;

Murakami, Koji ;

Sato, Takashi ;

Kojima, Yoshiki ;

Ebi, Hiromichi ;

Mukai, Hirofumi ;

Tahara, Makoto ;

Shimokata, Kaoru ;

Minami, Hironobu .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (01) :44-48

[60]

EVALUATION OF OXYGENATION STATUS DURING FRACTIONATED RADIOTHERAPY IN HUMAN NONSMALL CELL LUNG CANCERS USING [F-18] FLUOROMISONIDAZOLE POSITRON EMISSION TOMOGRAPHY [J].

KOH, WJ ;

BERGMAN, KS ;

RASEY, JS ;

PETERSON, LM ;

EVANS, ML ;

GRAHAM, MM ;

GRIERSON, JR ;

LINDSLEY, KL ;

LEWELLEN, TK ;

KROHN, KA ;

GRIFFIN, TW .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 33 (02) :391-398

← 1 2 3 4 5 6 7 8 9 10 →